☆ 4.6 Article

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis

Arunima Jaiswal et al.

Summary: Resistance to DT2216 is rare in a wide variety of T-ALL cells, and is correlated with decreased degradation of BCL-XL. Resistance to DT2216 in T-ALL is not predicted by initial protein levels. These findings suggest that a phase 2 clinical trial of DT2216 in T-ALL should be widely available, not limited to a subset of patients.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

添加到收藏夹

Letter Oncology

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Sajid Khan et al.

Summary: KRAS(G12C) mutation is associated with tumor identification and its sensitivity to current treatments. This study demonstrates the synergistic effect of sotorasib and DT2216 combination therapy on certain KRAS(G12C) tumor cell lines, leading to enhanced efficacy in treating these tumors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment

Krisstina Gowin et al.

Summary: Plasma cell leukemia, whether primary or secondary, is a rare and aggressive blood disorder with poor survival rates despite effective therapies. Recent molecular studies using gene expression profiling and whole exome sequencing have provided new insights into the disease, potentially leading to improved prognosis and treatment strategies.

LEUKEMIA RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

Ryan Kolb et al.

Summary: The pharmacological degradation of BCL-X-L preferentially induces apoptosis of tumor-infiltrating Tregs, promoting CD8 T cell activation and effective suppression of tumor growth without causing damage to normal tissues or thrombocytopenia. This finding suggests that targeting BCL-X-L could be a potential therapeutic strategy for cancer immunotherapy.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

A clinical perspective on plasma cell leukemia; current status and future directions

Sherilyn A. Tuazon et al.

Summary: Primary plasma cell leukemia (pPCL) is an aggressive disorder with a poor prognosis, and diagnosis is based on the percentage of peripheral blood plasma cells. Treatment typically involves combination therapy, including various agents, with clinical trials being crucial for improving outcomes.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Review Oncology

Targeting MCL-1 in cancer: current status and perspectives

Haolan Wang et al.

Summary: MCL-1, an antiapoptotic protein, is frequently overexpressed in many tumor types and closely associated with tumorigenesis, poor prognosis, and drug resistance. Its central role in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Progress has been made towards MCL-1 inhibitors and some have entered clinical trials.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia

Allison Kupsh et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)

添加到收藏夹

Article Cell Biology

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

Carolane Seiller et al.

CELL DEATH & DISEASE (2020)

添加到收藏夹

Article Oncology

DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Yonghan He et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Letter Oncology

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

Shannon M. Matulis et al.

LEUKEMIA (2019)

添加到收藏夹

Review Immunology

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma

Benjamin G. Barwick et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

Lina Benaniba et al.

BMC CANCER (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Sajid Khan et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Hematology

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez-Bougie et al.

BLOOD (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Measurement of BH3-only protein tolerance

Haiming Dai et al.

CELL DEATH AND DIFFERENTIATION (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

BCL-2 family proteins: changing partners in the dance towards death

Justin Kale et al.

CELL DEATH AND DIFFERENTIATION (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

MOMP, cell suicide as a BCL-2 family business

Halime Kalkavan et al.

CELL DEATH AND DIFFERENTIATION (2018)

添加到收藏夹

Letter Hematology

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma

Christelle Dousset et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

添加到收藏夹

Article Hematology

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

Jia-Nan Gong et al.

BLOOD (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

Kristopher A. Sarosiek et al.

FEBS JOURNAL (2016)

添加到收藏夹

Article Cell Biology

Physiological restraint of Bak by Bcl-xL is essential for cell survival

Erinna F. Lee et al.

GENES & DEVELOPMENT (2016)

添加到收藏夹

Article Cell Biology

Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane

Katelyn L. O'Neill et al.

GENES & DEVELOPMENT (2016)

添加到收藏夹

Letter Biochemical Research Methods

A Simple Flow Cytometry-Based Barcode for Routine Authentication of Multiple Myeloma and Mantle Cell Lymphoma Cell Lines

Sophie Maiga et al.

CYTOMETRY PART A (2015)

添加到收藏夹

Article Cell Biology

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

Robert L. Thomas et al.

GENES & DEVELOPMENT (2013)

添加到收藏夹

Article Oncology

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Hematology

ABT-737 is highly effective against molecular subgroups of multiple myeloma

Linda Bodet et al.

BLOOD (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

Fabien Llambi et al.

MOLECULAR CELL (2011)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mimicking the BH3 domain to kill cancer cells

T. Ni Chonghaile et al.

ONCOGENE (2008)

添加到收藏夹

Article Hematology

The molecular classification of multiple myeloma

Fenghuang Zhan et al.

BLOOD (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex

P Gomez-Bougie et al.

ONCOGENE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.